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L E T T E R  T O  T H E  E D I T O R
Antenatal corticosteroid therapy and COVID-19: 
Pathophysiological considerations
Sir,
The severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) pandemic has presented many challenges in health care, in-
cluding obstetrics. Therefore, we read with great interest the special 
editorial published in AOGS regarding clinical recommendations for 
the management of coronavirus disease 2019 (COVID-19) in preg-
nant women.1 As illustrated by the authors, the usefulness and safety 
of corticosteroids as an adjuvant therapy for COVID-19 pneumonia 
remains controversial. Corticosteroids may diminish the inflamma-
tory response, a major factor for lung damage and acute respiratory 
distress syndrome in viral respiratory tract infection. However, pre-
vious studies on corticosteroid therapy in SARS coronavirus and 
Middle East respiratory syndrome coronavirus illustrated delayed 
viral clearance, with no survival benefit and perhaps even adverse 
outcomes.2 Some patients with COVID-19 exhibit biphasic disease 
evolution with a mild presentation followed by a secondary respira-
tory deterioration due to a cytokine storm, despite decreasing viral 
load.2 Therefore, timing of corticosteroid therapy might be particu-
larly consequential, with early administration reducing inflammatory 
response and viral clearance during the initial phase.
While acknowledging the recommendations to administer corti-
costeroids for fetal lung maturation when preterm delivery is antic-
ipated,1 one must also consider the renin-angiotensin-aldosterone 
system, which is closely linked to the pathophysiology of COVID-19. 
SARS-CoV-2 gains access to its target cell by exploiting the mem-
brane-bound angiotensin-converting enzyme 2 (ACE2).3 ACE2 
converts angiotensin II to angiotensin (1-7), which has vasodilator, 
anti-proliferative, and anti-fibrotic functional effects, in contrast to 
those of angiotensin II.3 It is thought that viral infection downreg-
ulates ACE2, resulting in disproportionate angiotensin II activity, 
which may be a possible mechanism for organ injury in COVID-19. 
Animal studies have illustrated that glucocorticoids are potent in-
ducers of ACE activity in the lung and so modulate local levels of 
angiotensin II, increase angiotensin II precursor processing, and up-
regulate angiotensin II receptors in vascular smooth muscle cells.4,5 
As angiotensin II seems to play a key role in the pathophysiology 
of COVID-19, its potentiation by corticosteroids might have a detri-
mental effect. Indeed, corroborating this theory, a small study illus-
trated correlation between increased plasma levels of angiotensin II, 
total viral load and lung injury severity.4
Despite the importance of antenatal lung maturation for neonates, 
uncertainties remain as to whether corticosteroids have any adverse 
effect on the clinical course of COVID-19 in the mother, and there is 
an urgent need to gather sufficient clinical data. Until then, especially 
during the early phase of the disease, we would proceed with caution 
regarding the administration of antenatal corticosteroids, considering 
the mother’s clinical status and gestational age of the fetus, and en-
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